Serina Therapeutics, Inc.(SER)Earnings, Financials & Key Ratios
SER•NYSE
$1.81
$20M mkt cap·Price updated May 7, 2026
AboutSerina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.Show more
- Revenue$56K-98.2%
- EBITDA-$17M-454.6%
- Net Income-$11M-311.4%
- EPS (Diluted)-1.51-339.7%
- Gross Margin-246.43%-353.7%
- EBITDA Margin-30096.43%-31125.4%
- Operating Margin-30442.86%-30576.4%
- Net Margin-19894.64%-12005.1%
- ROE-2193.11%
- Debt/Equity0.53
- Interest Coverage-32.41-478.0%
SER Key Insights
Serina Therapeutics, Inc. (SER) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓High quality earnings: Operating CF exceeds net income
- ✓Share count reduced 12.5% through buybacks
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 10 (bottom 10%)
- ✗Sales declining 49.6% over 5 years
- ✗Trading more than 30% below 52-week high
- ✗Expensive at 26.2x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
SER Price & Volume
Serina Therapeutics, Inc. (SER) stock price & volume — 10-year historical chart
Loading chart...
SER Growth Metrics
Serina Therapeutics, Inc. (SER) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-49.63%
3 Years-73.59%
TTM-96.27%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-152.87%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM69.3%
Return on Capital
10 Years-368.76%
5 Years-503.95%
3 Years-511.09%
Last Year-286.21%
SER Peer Comparison
Serina Therapeutics, Inc. (SER) competitors in Drug Delivery Technology Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PRTA | 566.86M | 10.53 | -2.32 | -92.84% | -260.92% | -49.88% | 0.05 | |
 ACAD | 3.86B | 22.57 | 9.85 | 11.87% | 34.3% | 35.65% | 0.04 | |
 NRXP | 84.71M | 3.06 | -2.28 | -157.28% | ||||
 BIIB | 28.25B | 191.38 | 21.67 | 1.39% | 13.92% | 7.55% | 0.38 | |
 ALNY | 39.48B | 295.91 | 127 | 65.19% | 13.46% | 98.29% | 1.62 | |
 IONS | 12.56B | 76.02 | -31.94 | 33.87% | -30.87% | -58.57% | 5.35 | |
 ARVN | 651.76M | 10.19 | -7.96 | -0.3% | -30.77% | -14.25% | 0.02 | |
 PTGX | 6.36B | 98.85 | -48.22 | -89.41% | -6.48% | -17.76% | 0.02 |
Compare SER vs Peers
Serina Therapeutics, Inc. (SER) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SER Income Statement
Serina Therapeutics, Inc. (SER) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 1.67M | 1.4M | 1.4M | 1.73M | 54K | 3.04M | 500K | 3.15M | 56K | 116K |
| Revenue Growth % | - | -15.73% | -0.57% | 23.78% | -96.88% | 5528.12% | -83.55% | 530.6% | -98.22% | -96.27% |
| Cost of Goods Sold | 911K | 685K | 841K | 998.5K | 1.28M | 0 | 0 | 90K | 194K | 50K |
| COGS % of Revenue | 54.68% | 48.79% | 60.24% | 57.78% | 2372.22% | - | - | 2.85% | 346.43% | - |
| Gross Profit | 755K▲ 0% | 719K▼ 4.8% | 555K▼ 22.8% | 729.5K▲ 31.4% | -1.23M▼ 268.2% | 3.04M▲ 347.7% | 500K▼ 83.5% | 3.06M▲ 512.6% | -138K▼ 104.5% | 66K▲ 0% |
| Gross Margin % | 45.32% | 51.21% | 39.76% | 42.22% | -2272.22% | 100% | 100% | 97.15% | -246.43% | 56.9% |
| Gross Profit Growth % | - | -4.77% | -22.81% | 31.44% | -268.2% | 347.69% | -83.55% | 512.6% | -104.51% | - |
| Operating Expenses | 13.49M | 9.14M | 11M | 13.29M | 9.18M | 4.67M | 2.77M | 6.19M | 16.91M | 23.43M |
| OpEx % of Revenue | 809.96% | 650.71% | 787.97% | 769.01% | 17000% | 153.68% | 554.07% | 196.38% | 30196.43% | - |
| Selling, General & Admin | 5.62M | 3.87M | 5.65M | 7.94M | 5.6M | 1.3M | 1.29M | 3.89M | 9.43M | 11.34M |
| SG&A % of Revenue | 337.46% | 275.57% | 404.51% | 459.64% | 10366.67% | 42.7% | 257.76% | 123.5% | 16839.29% | - |
| Research & Development | 7.87M | 5.27M | 5.35M | 5.35M | 3.58M | 3.8M | 1.57M | 2.39M | 7.48M | 12.1M |
| R&D % of Revenue | 472.51% | 375.14% | 383.45% | 309.38% | 6633.33% | 124.99% | 314.62% | 75.74% | 13357.14% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | -425.57K | -91.5K | -90K | 0 | -16K |
| Operating Income | -12.74M▲ 0% | -8.42M▲ 33.9% | -10.45M▼ 24.1% | -12.56M▼ 20.2% | -10.41M▲ 17.1% | -1.63M▲ 84.3% | -2.27M▼ 39.2% | -3.13M▼ 37.8% | -17.05M▼ 444.8% | -23.36M▲ 0% |
| Operating Margin % | -764.65% | -599.5% | -748.21% | -726.79% | -19272.22% | -53.68% | -454.07% | -99.24% | -30442.86% | -20141.38% |
| Operating Income Growth % | - | 33.93% | -24.09% | -20.24% | 17.14% | 84.32% | -39.16% | -37.82% | -444.84% | - |
| EBITDA | -11.89M | -7.74M | -9.91M | -11.61M | -9.15M | -1.6M | -2.21M | -3.04M | -16.85M | -23.26M |
| EBITDA Margin % | -713.93% | -550.93% | -709.89% | -671.76% | -16948.15% | -52.58% | -441.82% | -96.38% | -30096.43% | -20050% |
| EBITDA Growth % | - | 34.97% | -28.12% | -17.13% | 21.16% | 82.54% | -38.23% | -37.57% | -454.59% | -109.27% |
| D&A (Non-Cash Add-back) | 845K | 682K | 535K | 951K | 1.25M | 33.37K | 61.27K | 90K | 194K | 106K |
| EBIT | -17.33M | -6.63M | -7.73M | -12.24M | -9.99M | -1.26M | -2.67M | 5.83M | -10.68M | -18.6M |
| Net Interest Income | 0 | 0 | 0 | 29K | -404K | 7.76K | -14.12K | -558K | -526K | -32K |
| Interest Income | 0 | 0 | 116K | 29K | 0 | 10.86K | 1.76K | 0 | 0 | 0 |
| Interest Expense | 25K | 12K | 0 | 0 | 404K | 3.09K | 15.88K | 558K | 526K | 32K |
| Other Income/Expense | -4.62M | 1.78M | 2.71M | 323K | 8K | 366.81K | -411.74K | 8.4M | 5.84M | 4.73M |
| Pretax Income | -17.36M▲ 0% | -6.64M▲ 61.8% | -7.73M▼ 16.5% | -12.24M▼ 58.3% | -10.4M▲ 15.0% | -1.26M▲ 87.8% | -2.68M▼ 112.1% | 5.27M▲ 296.4% | -11.21M▼ 312.7% | -18.63M▲ 0% |
| Pretax Margin % | -1041.72% | -472.72% | -553.8% | -708.1% | -19257.41% | -41.61% | -536.42% | 167.11% | -20012.5% | -16061.21% |
| Income Tax | 0 | -57K | 0 | 148K | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0.86% | 0% | -1.21% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -15.49M▲ 0% | -6.58M▲ 57.5% | -7.5M▼ 14.0% | -12.15M▼ 62.0% | -10.87M▲ 10.6% | -1.26M▲ 88.4% | -2.68M▼ 112.1% | 5.27M▲ 296.4% | -11.14M▼ 311.4% | -18.59M▲ 0% |
| Net Margin % | -929.89% | -468.66% | -537.39% | -703.36% | -20120.37% | -41.61% | -536.42% | 167.11% | -19894.64% | -16022.41% |
| Net Income Growth % | - | 57.53% | -14.01% | -62.01% | 10.61% | 88.36% | -112.07% | 296.45% | -311.44% | -152.87% |
| Net Income (Continuing) | -17.36M | -6.64M | -7.73M | -12.38M | -10.4M | -1.26M | -2.68M | 5.27M | -11.21M | -18.63M |
| Discontinued Operations | 0 | 0 | 0 | 0 | -471K | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 1.04M | 1.04M | 784K | 399K | -280K | -43K | -103K | 0 | -133K | -166K |
| EPS (Diluted) | -15.21▲ 0% | -6.46▲ 57.5% | -7.56▼ 17.0% | -11.47▼ 51.7% | -10.14▲ 11.6% | -8.05▲ 20.6% | -2.49▲ 69.1% | 0.63▲ 125.3% | -1.51▼ 339.7% | -1.80▲ 0% |
| EPS Growth % | - | 57.53% | -17.03% | -51.72% | 11.6% | 20.61% | 69.07% | 125.3% | -339.68% | 69.3% |
| EPS (Basic) | -15.21 | -6.46 | -7.56 | -11.47 | -10.14 | -8.05 | -2.49 | 0.63 | -1.51 | - |
| Diluted Shares Outstanding | 1.02M | 1.02M | 992.72K | 1.06M | 1.07M | 1.08M | 1.08M | 8.41M | 7.36M | 10.34M |
| Basic Shares Outstanding | 1.02M | 1.02M | 992.72K | 1.06M | 1.07M | 1.08M | 1.08M | 8.41M | 7.36M | 10.34M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
SER Balance Sheet
Serina Therapeutics, Inc. (SER) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 688K | 7.59M | 7.85M | 4.05M | 2.28M | 2.23M | 2.45M | 7.62M | 5.68M | 11.5M |
| Cash & Short-Term Investments | 259K | 7.38M | 6.71M | 2.35M | 527K | 584K | 645K | 7.62M | 3.67M | 8.62M |
| Cash Only | 259K | 7.38M | 6.71M | 2.35M | 527K | 584K | 645K | 7.62M | 3.67M | 8.62M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 308K | 107K | 131K | 363K | 326K | 25K | 4K | 0 | 0 | 0 |
| Days Sales Outstanding | 67.48 | 27.82 | 34.25 | 76.68 | 2.2K | 3 | 2.92 | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 121K | 111K | 1.01M | 1.34M | 1.43M | 1.63M | 1.8M | 0 | 77K | 1.89M |
| Total Non-Current Assets | 2.54M | 2.04M | 2.82M | 3.39M | 1.64M | 920K | 788K | 1.35M | 1.05M | 916K |
| Property, Plant & Equipment | 195K | 129K | 90K | 1.13M | 0 | 0 | 0 | 1.35M | 1.05M | 892K |
| Fixed Asset Turnover | 8.54x | 10.88x | 15.51x | 1.53x | - | - | - | 2.34x | 0.05x | 0.12x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 2.15M | 1.59M | 0 | 738K | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 50K | 50K | 50K | 0 | 0 | 0 |
| Other Non-Current Assets | 2.34M | 1.91M | 2.73M | 111K | 0 | 870K | 0 | 0 | 0 | 24K |
| Total Assets | 3.22M▲ 0% | 9.63M▲ 198.8% | 10.67M▲ 10.8% | 7.44M▼ 30.3% | 3.92M▼ 47.3% | 3.15M▼ 19.6% | 3.24M▲ 2.8% | 8.97M▲ 176.7% | 6.72M▼ 25.0% | 12.41M▲ 0% |
| Asset Turnover | 0.52x | 0.15x | 0.13x | 0.23x | 0.01x | 0.96x | 0.15x | 0.35x | 0.01x | 0.01x |
| Asset Growth % | - | 198.82% | 10.8% | -30.26% | -47.26% | -19.64% | 2.76% | 176.7% | -25.02% | -12.57% |
| Total Current Liabilities | 25.6M | 1.31M | 2.44M | 3.3M | 5.36M | 8.97M | 10.08M | 1.41M | 2.37M | 8.79M |
| Accounts Payable | 261K | 75K | 150K | 420K | 761K | 193K | 568K | 580K | 744K | 2.73M |
| Days Payables Outstanding | 104.57 | 39.96 | 65.1 | 153.53 | 216.83 | - | - | 2.35K | 1.4K | 11.62K |
| Short-Term Debt | 0 | 0 | 0 | 428K | 2.4M | 7.14M | 7.65M | 0 | 0 | 3.05M |
| Deferred Revenue (Current) | 264K | 180K | 317K | 283K | 275K | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 25.07M | 1.06M | 1.97M | 2.17M | 1.93M | 1.63M | 1.67M | 250K | 1.06M | 2.39M |
| Current Ratio | 0.03x | 5.79x | 3.22x | 1.23x | 0.43x | 0.25x | 0.24x | 5.39x | 2.40x | 2.40x |
| Quick Ratio | 0.03x | 5.79x | 3.22x | 1.23x | 0.43x | 0.25x | 0.24x | 5.39x | 2.40x | 2.40x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 0 | 0 | 1.53M | 3.96M | 6.06M | 10.48M | 39.85M | 3.85M | 2.03M |
| Long-Term Debt | 0 | 0 | 0 | 1.53M | 3.9M | 6.06M | 10.48M | 2.98M | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 462K | 268K | 828K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 36.4M | 3.58M | 11.61M |
| Total Liabilities | 25.6M | 1.31M | 2.44M | 4.83M | 9.32M | 15.03M | 20.56M | 41.26M | 6.22M | 10.82M |
| Total Debt | 0 | 0 | 0 | 1.96M | 6.3M | 13.2M | 18.12M | 3.44M | 268K | 3.2M |
| Net Debt | -259K | -7.38M | -6.71M | -396K | 5.77M | 12.62M | 17.48M | -4.17M | -3.4M | -5.42M |
| Debt / Equity | - | - | - | 0.75x | - | - | - | - | 0.53x | 0.53x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.14x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.23x |
| Interest Coverage | -509.56x | -701.42x | - | - | -25.76x | -527.31x | -142.99x | -5.61x | -32.41x | -581.22x |
| Total Equity | -22.38M▲ 0% | 8.32M▲ 137.2% | 8.23M▼ 1.1% | 2.62M▼ 68.2% | -5.4M▼ 306.2% | -11.88M▼ 120.1% | -17.32M▼ 45.8% | -32.29M▼ 86.5% | 508K▲ 101.6% | 1.59M▲ 0% |
| Equity Growth % | - | 137.18% | -1.06% | -68.21% | -306.19% | -120.07% | -45.81% | -86.51% | 101.57% | 270.11% |
| Book Value per Share | -21.96 | 8.17 | 8.29 | 2.47 | -5.04 | -11.02 | -16.05 | -3.84 | 0.07 | 0.15 |
| Total Shareholders' Equity | -23.42M | 7.28M | 7.45M | 2.22M | -5.12M | -11.83M | -17.21M | -32.29M | 641K | 1.76M |
| Common Stock | 3K | 3K | 4K | 4K | 4K | 4K | 4K | 0 | 1K | 1K |
| Retained Earnings | -59.97M | -66.55M | -74.05M | -86.21M | -97.07M | -105.75M | -116.21M | -33.18M | -44.32M | -60.16M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 58K | 68K | -2K | 69K | 143K | 0 | 0 | 0 | 0 | -4K |
| Minority Interest | 1.04M | 1.04M | 784K | 399K | -280K | -43K | -103K | 0 | -133K | -166K |
SER Cash Flow Statement
Serina Therapeutics, Inc. (SER) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -8.43M | -6.29M | -8M | -10.16M | -7.82M | -2.25M | -2.08M | -2.48M | -17.14M | -17.14M |
| Operating CF Margin % | -505.82% | -447.65% | -572.71% | -587.96% | -14475.93% | -74.06% | -415.12% | -78.53% | -30601.79% | - |
| Operating CF Growth % | - | 25.42% | -27.21% | -27.08% | 23.06% | 71.21% | 7.78% | -19.29% | -592.12% | -4043.43% |
| Net Income | -15.49M | -6.58M | -7.5M | -12.15M | -10.39M | -1.26M | -2.68M | 5.27M | -11.21M | -18.59M |
| Depreciation & Amortization | 845K | 682K | 535K | 951K | 1.25M | 33.37K | 61.27K | 90K | 194K | 106K |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 | 82.94K | 7.11K | 25K | 2.6M | 2.83M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 5.42M | -388K | -793K | 1.45M | 1.58M | -347.59K | 550.04K | -7.94M | -5.4M | -3.21M |
| Working Capital Changes | 1.31M | 776K | 211K | -410K | -260K | -754.79K | -11.94K | 81K | -3.32M | 2.38M |
| Change in Receivables | -57K | 322K | -24K | -232K | -30K | 1.27M | 1.11K | 0 | 65K | 14K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 1.24M | 267K | 648K | 169K | 382K | -367.29K | -2.13K | 393K | -1.66M | 1.06M |
| Cash from Investing | -28K | 5K | 1.33M | -361K | -20K | 823.32K | 980.94K | -504K | -22K | -64K |
| Capital Expenditures | -23K | -1K | -1.89M | -641K | -20K | -108.43K | -9.68K | -504K | -22K | -64K |
| CapEx % of Revenue | 1.38% | 0.07% | 135.6% | 37.09% | 37.04% | 3.57% | 1.94% | 15.98% | 39.29% | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -5K | 6K | 5K | -74K | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 7.25M | 13.28M | 6M | 6.26M | 5.96M | 1.08M | 1.31M | 10.07M | 13.21M | 21.96M |
| Debt Issued (Net) | 0 | 0 | 0 | 1.76M | 5.96M | -12.91K | 1.31M | 10.05M | 2.88M | 5.02M |
| Equity Issued (Net) | 2.45M | 11.97M | 6M | 4.5M | 0 | 90.15K | 4.42K | 15K | 5M | 12.02M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 4.81M | 1.3M | 0 | 0 | 0 | 1M | 0 | 0 | 5.34M | 4.92M |
| Net Change in Cash | -1.2M▲ 0% | 7.12M▲ 692.5% | -668K▼ 109.4% | -4.36M▼ 551.9% | -1.82M▲ 58.1% | -350.21K▲ 80.8% | 217.38K▲ 162.1% | 7.09M▲ 3160.1% | -3.95M▼ 155.7% | 5.38M▲ 0% |
| Free Cash Flow | -8.45M▲ 0% | -6.29M▲ 25.6% | -9.89M▼ 57.3% | -10.8M▼ 9.2% | -7.84M▲ 27.4% | -2.36M▲ 69.9% | -2.09M▲ 11.6% | -2.98M▼ 42.9% | -17.16M▼ 475.8% | -16.53M▲ 0% |
| FCF Margin % | -507.2% | -447.72% | -708.31% | -625.06% | -14512.96% | -77.63% | -417.06% | -94.51% | -30641.07% | -14249.14% |
| FCF Growth % | - | 25.61% | -57.3% | -9.23% | 27.44% | 69.9% | 11.61% | -42.9% | -475.81% | -32.08% |
| FCF per Share | -8.29 | -6.17 | -9.96 | -10.19 | -7.32 | -2.19 | -1.93 | -0.35 | -2.33 | -2.33 |
| FCF Conversion (FCF/Net Income) | 0.54x | 0.96x | 1.07x | 0.84x | 0.72x | 1.78x | 0.77x | -0.47x | 1.54x | 0.89x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 3.09K | 15.88K | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SER Key Ratios
Serina Therapeutics, Inc. (SER) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -79.1% | -90.66% | -224.08% | - | - | - | - | -2193.11% | -1400.87% |
| Return on Invested Capital (ROIC) | -668.72% | -634.83% | -503.03% | -601.79% | -219.29% | -375.47% | - | - | 522.53% |
| Gross Margin | 51.21% | 39.76% | 42.22% | -2272.22% | 100% | 100% | 97.15% | -246.43% | 56.9% |
| Net Margin | -468.66% | -537.39% | -703.36% | -20120.37% | -41.61% | -536.42% | 167.11% | -19894.64% | -16022.41% |
| Debt / Equity | - | - | 0.75x | - | - | - | - | 0.53x | 0.53x |
| Interest Coverage | -701.42x | - | - | -25.76x | -527.31x | -142.99x | -5.61x | -32.41x | -581.22x |
| FCF Conversion | 0.96x | 1.07x | 0.84x | 0.72x | 1.78x | 0.77x | -0.47x | 1.54x | 0.89x |
| Revenue Growth | -15.73% | -0.57% | 23.78% | -96.88% | 5528.12% | -83.55% | 530.6% | -98.22% | -96.27% |
SER Frequently Asked Questions
Serina Therapeutics, Inc. (SER) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Serina Therapeutics, Inc. (SER) reported $0.1M in revenue for fiscal year 2024. This represents a 93% decrease from $1.7M in 2016.
Serina Therapeutics, Inc. (SER) saw revenue decline by 98.2% over the past year.
Serina Therapeutics, Inc. (SER) reported a net loss of $18.6M for fiscal year 2024.
Dividend & Returns
Serina Therapeutics, Inc. (SER) has a return on equity (ROE) of -2193.1%. Negative ROE indicates the company is unprofitable.
Serina Therapeutics, Inc. (SER) had negative free cash flow of $16.5M in fiscal year 2024, likely due to heavy capital investments.
Explore More SER
Serina Therapeutics, Inc. (SER) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates